| http://www.w3.org/ns/prov#value | - Sanofi and Genzyme have presented additional data analysis demonstrating Lemtrada's superiority over Rebif in reducing disability in MS. However, due to Lemtrada's potential to lead to the development of autoimmune adverse events, Datamonitor expects that the drug will be used at later lines of therapy and in patients with severe forms of MS.
|
